Trial Profile
An Exploratory Tumor Biopsy-Driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Immunomodulatory Treatment-Naïve Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Receiving REGN2810 (Anti-PD-1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 17 Mar 2020 Status changed from active, no longer recruiting to completed.
- 11 Feb 2020 Planned End Date changed from 13 Feb 2020 to 20 May 2020.
- 14 Aug 2019 Planned End Date changed from 11 Dec 2020 to 13 Feb 2020.